EnterNext félicite Pixium Vision pour le succès de son introduction en Bourse

Back

Paris 18 June 2014 – EnterNext, the Euronext subsidiary dedicated to promoting and growing the market for SMEs[1], today congratulated Pixium Vision, specialised in developing systems to restore the vision of patients who have lost their sight, on its listing in Compartment C of Euronext’s regulated market in Paris.

Founded in 2011 by Bernard Gilly, Professor José-Alain Sahel, and a number of scientists from well-known academic and technology institutions, Pixium Vision develops Vision Restoration Systems (VRS) for people who have lost their sight due to degenerative conditions affecting retinal photoreceptors.

The company has developed IRIS®, a system combining several high-tech components with surgery and re-education. Pixium Vision’s VRSs aim to allow people who have lost their sight to live more autonomously. IRIS1 is currently undergoing clinical tests. To date patients are supporting the implants well, and improvements have been observed in the visual perception of blind patients. Pixium Vision is also developing PRIMA, a second VRS, that uses an implant positioned under the retina. PRIMA is currently in the preclinical development stage.

Pixium Vision (ticker code: PIX) was listed through the admission to trading of the 7,964,554 shares making up its equity and the issue of 4,166,666new shares issued in a Global Offering[2], including full exercise of the extension option and before possible exercise of the over-allotment.

The admission and issue price of Pixium Vision shares was set at €8.28 per share. Market capitalisation was around €100.4million on the day of listing. Altogether the offering raised €34.5million.

“We are delighted to welcome Pixium Vision to EnterNext. Listing will raise the group’s visibility on international markets and give it access to a larger pool of investors, allowing it to develop and successfully market its innovative technology,” said Eric Forest, Chairman and CEO of EnterNext.

Pixium Vision’s Chairman and CEO Bernard Gilly added: “Our successful IPO reflects investor confidence in Pixium Vision’s strategy. We are convinced that Pixium Vision, drawing on our complementary IRIS® and PRIMA technologies, is uniquely positioned to become a world leader in vision restoration systems, helping people who have lost their sight live more autonomously.”



[1]Small and medium-size companies
[2]
The Global Offering was made up of a Public Offering that included an Open Price Public Offering and a Global Placement with institutional investors in France and other countries.

Press Release Footer

About Euronext 
Euronext is the leading pan-European market infrastructure, connecting European economies to global capital markets, to accelerate innovation and sustainable growth. It operates regulated exchanges in Belgium, France, Ireland, Italy, the Netherlands, Norway and Portugal. With close to 2,000 listed issuers and around €5.8 trillion in market capitalisation as of end June 2022, it has an unmatched blue-chip franchise and a strong diverse domestic and international client base. Euronext operates regulated and transparent equity and derivatives markets, one of Europe’s leading electronic fixed income trading markets and is the largest centre for debt and funds listings in the world. Its total product offering includes Equities, FX, Exchange Traded Funds, Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. The Group provides a multi-asset clearing house through Euronext Clearing, and custody and settlement services through Euronext Securities central securities depositories in Denmark, Italy, Norway and Portugal. Euronext also leverages its expertise in running markets by providing technology and managed services to third parties. In addition to its main regulated market, it also operates a number of junior markets, simplifying access to listing for SMEs.  
For the latest news, follow us on Twitter (twitter.com/euronext) and LinkedIn (linkedin.com/euronext).

Disclaimer
This press release is for information purposes only and is not a recommendation to engage in investment activities. This press release is provided “as is” without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this publication may be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext’s subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with this publication shall vest in Euronext.

This press release speaks only as of this date. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is located at www.euronext.com/terms-use.

© 2022, Euronext N.V. - All rights reserved.